Exact Sciences: Make It Stop!
October 08, 2015 at 11:53 AM EDT
If it wasn’t bad enough that Exact Sciences (EXAS) lost half it’s value on Tuesday after an unfavorable designation for its colon-cancer test, its shares have lost almost a quarter more today. It sure didn’t help that Wedbush analyst Zarak Khurshid cut his target price to $7 from $18. He explains why: With this note […]
